Applicants: Tilla S. Worgall, et al.

Serial No.: Not Yet Known

Filed: Herewith

Page 2

## Amendments to the Claims:

Please amend the claims by replacing all prior versions and listings of the claims as follows:

## Listing of Claims:

Claim 1 (original) A method for decreasing the amount of mSREBP in a cell characterized by an elevated level of mSREBP comprising contacting the cell with an agent that specifically inhibits de novo synthesis of ceramide in the cell, thereby decreasing the amount of mSREBP in the cell.

## Claims 2-4 (canceled)

- Claim 5 (currently amended) The method of claim 1,  $\frac{2}{7}$ ,  $\frac{3}{7}$  or  $\frac{4}{7}$  wherein the cell is a human cell.
- Claim 6 (currently amended) The method of claim 1,  $\frac{2}{3}$  or  $\frac{4}{7}$  wherein the cell is a hepatocyte.
- Claim 7 (currently amended) The method of claim 1,  $\frac{2}{7}$ ,  $\frac{3}{7}$  or  $\frac{4}{7}$  wherein the cell is an adipocyte.
- Claim 8 (currently amended) The method of claim 1, 2, 3 or 4, wherein the agent specifically inhibits the activity of an enzyme which catalyzes part of the *de novo* ceramide pathway.
- Claim 9 (original) The method of claim 8, wherein the enzyme is serine-palmitoyl transferase or ceramide synthase.

Applicants: Tilla S. Worgall, et al.

Serial No.: Not Yet Known

Filed: Herewith

Page 3

- Claim 10 (currently amended) The method of claim 1, 2, 3 or 4, wherein the agent inhibits the expression of an enzyme which catalyzes part of the *de novo* ceramide pathway.
- Claim 11 (original) The method of claim 10, wherein the enzyme is serine-palmitoyl transferase or ceramide synthase.
- Claim 12 (currently amended) The method of claim 1, 2, 3 or 4, wherein the agent is selected from the group consisting of (a) myriocin; (b) cycloserine; (c) Fumonisin B1; (d) PPMP; (e) compound D609; (f) methylthiodihydroceramide; (g) propanolol; and (h) resvaratrol.
- Claim 13 (original) A method for increasing the amount of mSREBP in a cell comprising contacting the cell with an agent that specifically increases de novo synthesis of ceramide in the cell, thereby increasing the amount of mSREBP in the cell.
- Claim 14 (original) The method of claim 13, wherein the cell is a human cell.
- Claim 15 (original) The method of claim 13, wherein the cell is a hepatocyte.
- Claim 16 (original) The method of claim 13, wherein the cell is an adipocyte.

Claims 17-43 (canceled)